Transforming growth factor beta receptor (TGF-β receptor (also commonly abbreviated as TGFBR; subtypes include TGFBR1, TGFBR2))

Transforming growth factor beta receptors are a family of transmembrane serine/threonine kinase receptors that mediate signaling of the TGF-β superfamily of growth factors, notably TGF-β1, TGF-β2, and TGF-β3[1][4][5]. The most prominent members are type I (TGFBR1/ALK5) and type II (TGFBR2) receptors, which form a heterotetrameric complex that transduces extracellular ligand binding into activation of downstream signaling pathways, principally via phosphorylation of SMAD transcription factors[4][5]. TGF-β receptor signaling exerts wide-ranging effects on cellular proliferation, apoptosis, differentiation, immune modulation, and extracellular matrix production[3][5]. Dysregulation or mutation of TGF-β receptors is implicated in carcinogenesis (where TGF-β signaling can play both tumor-suppressive and pro-oncogenic roles), tissue fibrosis, inflammatory and autoimmune diseases, and vascular disorders[1][4][5]. Drugs targeting TGF-β receptor pathways include kinase inhibitors, monoclonal antibodies, and ligand traps, with ongoing clinical development aimed at cancer, fibrotic, and autoimmune diseases, though adverse effects remain a therapeutic challenge due to the central role of this signaling axis in tissue repair and immune regulation[4][5].

Other names

TGF-β receptorTGF-beta receptorTGFBRTβRTGF-beta type I receptor (TGFBR1, ALK5)TGF-beta type II receptor (TGFBR2)Activin receptor-like kinase 5 (ALK5; for TGFBR1)

Small molecule inhibition of receptor serine/threonine kinase activity (e.g., TGFBR1 inhibitors block intracellular signaling) Monoclonal antibodies blocking ligand binding or receptor function Fusion proteins acting as ligand traps Inhibition of downstream SMAD signaling